ACAD Relative Valuation
ACAD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACAD is overvalued; if below, it's undervalued.
Historical Valuation
ACADIA Pharmaceuticals Inc (ACAD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.95. The fair price of ACADIA Pharmaceuticals Inc (ACAD) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：26.55
Fair
40.09
PE
1Y
3Y
5Y
Trailing
Forward
40.59
EV/EBITDA
ACADIA Pharmaceuticals Inc. (ACAD) has a current EV/EBITDA of 40.59. The 5-year average EV/EBITDA is 68.47. The thresholds are as follows: Strongly Undervalued below -548.78, Undervalued between -548.78 and -240.16, Fairly Valued between 377.09 and -240.16, Overvalued between 377.09 and 685.71, and Strongly Overvalued above 685.71. The current Forward EV/EBITDA of 40.59 falls within the Historic Trend Line -Fairly Valued range.
29.60
EV/EBIT
ACADIA Pharmaceuticals Inc. (ACAD) has a current EV/EBIT of 29.60. The 5-year average EV/EBIT is 1.82. The thresholds are as follows: Strongly Undervalued below -110.68, Undervalued between -110.68 and -54.43, Fairly Valued between 58.07 and -54.43, Overvalued between 58.07 and 114.32, and Strongly Overvalued above 114.32. The current Forward EV/EBIT of 29.60 falls within the Historic Trend Line -Fairly Valued range.
3.63
PS
ACADIA Pharmaceuticals Inc. (ACAD) has a current PS of 3.63. The 5-year average PS is 5.08. The thresholds are as follows: Strongly Undervalued below -0.85, Undervalued between -0.85 and 2.12, Fairly Valued between 8.05 and 2.12, Overvalued between 8.05 and 11.01, and Strongly Overvalued above 11.01. The current Forward PS of 3.63 falls within the Historic Trend Line -Fairly Valued range.
15.84
P/OCF
ACADIA Pharmaceuticals Inc. (ACAD) has a current P/OCF of 15.84. The 5-year average P/OCF is -24.41. The thresholds are as follows: Strongly Undervalued below -153.49, Undervalued between -153.49 and -88.95, Fairly Valued between 40.13 and -88.95, Overvalued between 40.13 and 104.67, and Strongly Overvalued above 104.67. The current Forward P/OCF of 15.84 falls within the Historic Trend Line -Fairly Valued range.
16.07
P/FCF
ACADIA Pharmaceuticals Inc. (ACAD) has a current P/FCF of 16.07. The 5-year average P/FCF is -0.56. The thresholds are as follows: Strongly Undervalued below -66.24, Undervalued between -66.24 and -33.40, Fairly Valued between 32.28 and -33.40, Overvalued between 32.28 and 65.12, and Strongly Overvalued above 65.12. The current Forward P/FCF of 16.07 falls within the Historic Trend Line -Fairly Valued range.
ACADIA Pharmaceuticals Inc (ACAD) has a current Price-to-Book (P/B) ratio of 4.90. Compared to its 3-year average P/B ratio of 6.93 , the current P/B ratio is approximately -29.34% higher. Relative to its 5-year average P/B ratio of 6.98, the current P/B ratio is about -29.88% higher. ACADIA Pharmaceuticals Inc (ACAD) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.75%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.57% , the current FCF yield is about -100.00% lower.
4.90
P/B
Median3y
6.93
Median5y
6.98
4.52
FCF Yield
Median3y
1.75
Median5y
-0.57
Competitors Valuation Multiple
The average P/S ratio for ACAD's competitors is 0.00, providing a benchmark for relative valuation. ACADIA Pharmaceuticals Inc Corp (ACAD) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 11.27%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ACAD increased by 44.69% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 13.09 to 25.76.
The secondary factor is the Revenue Growth, contributed 11.27%to the performance.
Overall, the performance of ACAD in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is ACADIA Pharmaceuticals Inc (ACAD) currently overvalued or undervalued?
What is ACADIA Pharmaceuticals Inc (ACAD) fair value?
How does ACAD's valuation metrics compare to the industry average?
What is the current P/B ratio for ACADIA Pharmaceuticals Inc (ACAD) as of Dec 05 2025?
What is the current FCF Yield for ACADIA Pharmaceuticals Inc (ACAD) as of Dec 05 2025?
What is the current Forward P/E ratio for ACADIA Pharmaceuticals Inc (ACAD) as of Dec 05 2025?